Global Custom Market Research Reports Provider Company

phone

Arbor Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 30
  • Category: Pharmaceuticals
  • Country: United States of America
Summary

Arbor Pharmaceuticals LLC (Arbor) is a healthcare products provider that develops prescription products for the hospital, cardiovascular and pediatric segments. The company offers licensing, manufacturing, development and commercialization of late-stage prescription products. It also offers generic prescription and development stage products. Arbors prescription products comprise edarbi, edarbyclor, bidil, nymalize, eryped, and erythromycin group of products. It offers products used in treatment areas including cardiovascular, emergency, pediatrics, psychiatry and endocrinology diseases. The company offers its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US.

Arbor Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 4
List of Figures 4
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
Venture Financing 13
XenoPort Raises USD20 Million in Venture Financing 13
Private Equity 14
KKR to Acquire Minority Stake in Arbor Pharma 14
Partnerships 15
Debiopharm Enters into Distribution Agreement with Arbor Pharma 15
Licensing Agreements 16
Dr. Reddys Labs Enters into Licensing Agreement with XenoPort for XP23829 16
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18
Equity Offering 19
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19
XenoPort Completes Public Offering Of Shares For US$85.8 Million 20
XenoPort Completes Public Offering Of Common Stock For US$46 Million 21
Debt Offering 22
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22
Acquisition 24
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 24
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 25
Arbor Pharmaceuticals LLC - Key Competitors 27
Arbor Pharmaceuticals LLC - Key Employees 28
Arbor Pharmaceuticals LLC - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List Of Tables

List of Tables
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arbor Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 8
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 11
XenoPort Raises USD20 Million in Venture Financing 13
KKR to Acquire Minority Stake in Arbor Pharma 14
Debiopharm Enters into Distribution Agreement with Arbor Pharma 15
Dr. Reddys Labs Enters into Licensing Agreement with XenoPort for XP23829 16
Reckitt Benckiser Pharma Enters Into Licensing Agreement With XenoPort For Arbaclofen Placarbil 17
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 18
XenoPort Files Shelf Registration Statement for Public Offering of Shares For USD150 Million 19
XenoPort Completes Public Offering Of Shares For US$85.8 Million 20
XenoPort Completes Public Offering Of Common Stock For US$46 Million 21
XenoPort Raises USD115 Million in Private Placement of 2.5% Notes Due 2022 22
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 24
Arbor Pharma Acquires Shares of XenoPort in a Tender Offer 25
Arbor Pharmaceuticals LLC, Key Competitors 27
Arbor Pharmaceuticals LLC, Key Employees 28
Arbor Pharmaceuticals LLC, Subsidiaries 29

List Of Figures

List of Figures
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arbor Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Synopsis UoM Ann Arbor Michigan Union Building Renovation Michigan - Project Profile contains information on the scope of the project including project overview and location. The profile also details

View Report

This report studies Artificial Carborundum in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from

View Report

In this report, the global Mobile Harbor Crane market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025,

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports